Semaglutide News and Research

Latest Semaglutide News and Research

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.

7 Oct 2025

Study finds surge in the use of weight loss drugs among bariatric surgery patients

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and Type 2 diabetes.

3 Oct 2025

Prediabetes can go into remission without weight loss

Research shows up to 22% of prediabetic individuals achieve remission without weight loss, emphasizing metabolic health over weight loss in diabetes prevention.

2 Oct 2025

Study shows prediabetes remission does not always require weight loss

Remission of prediabetes can occur even without weight loss, protecting against type 2 diabetes in up to 22% of individuals. Metabolic improvements, healthier fat distribution, and enhanced β-cell function, not body weight change, drive this benefit.

30 Sep 2025

Cannabidiol shows promise for obesity and metabolic syndrome

Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models of obesity and metabolic syndrome. However, human evidence is still limited, highlighting the need for rigorous trials before clinical use.

29 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Georgia State scientist receives $25,000 grant to develop mechanisms for treating obesity

Chong Hyun Shin, a research associate professor in the Institute for Biomedical Sciences at Georgia State University, has received a $25,000 grant to develop mechanisms for treating obesity and obesity-related metabolic dysfunctions.

23 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Study points to a surprising new ally in the fight against type 2 diabetes

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation - and pointing to a surprising new ally in the fight against type 2 diabetes.

19 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Closed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.

Closed Loop Medicine Ltd (CLM), a leader in personalized pharmaceutical dosing, today announced the U.S. launch of WeDosify, which enables clinicians to personalize GLP-1 titration at scale.

19 Sep 2025

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase III clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

New genetic test can help predict how people will respond to weight-loss medications

Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

Semaglutide News and Research

Latest Semaglutide News and Research

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

Study finds surge in the use of weight loss drugs among bariatric surgery patients

Prediabetes can go into remission without weight loss

Study shows prediabetes remission does not always require weight loss

Cannabidiol shows promise for obesity and metabolic syndrome

Scientists outline how future therapies could change type 1 diabetes care

Georgia State scientist receives $25,000 grant to develop mechanisms for treating obesity

Orforglipron pill improves heart and metabolic risk factors in trial

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Study points to a surprising new ally in the fight against type 2 diabetes

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Closed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Scientists unveil new obesity drug that reprograms fat and energy use

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

New genetic test can help predict how people will respond to weight-loss medications

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Semaglutide News and Research

Latest Semaglutide News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in